3K7A Stock Overview
A psychedelics and wellness company, develops psychedelic medicine to reduce trauma.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Silo Wellness Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0005 |
| 52 Week High | CA$0.018 |
| 52 Week Low | CA$0.0001 |
| Beta | 0.66 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -96.67% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3K7A | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.8% | -1.0% |
| 1Y | -96.7% | -19.2% | 6.4% |
Return vs Industry: 3K7A underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 3K7A underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 3K7A volatility | |
|---|---|
| 3K7A Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 3K7A's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 3K7A's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Mike Arnold | www.silowellness.com |
Silo Wellness Inc., a psychedelics and wellness company, develops psychedelic medicine to reduce trauma. The company develops and sells psilocybin-free functional mushroom tinctures; and the formulation of a psilocybin nasal spray in Jamaica. It also offers a portfolio of functional mushroom products: Jamaican and Oregon psychedelic wellness retreats.
Silo Wellness Inc. Fundamentals Summary
| 3K7A fundamental statistics | |
|---|---|
| Market cap | €1.04m |
| Earnings (TTM) | €466.92k |
| Revenue (TTM) | €252.08k |
2.2x
P/E Ratio4.1x
P/S RatioIs 3K7A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3K7A income statement (TTM) | |
|---|---|
| Revenue | US$275.89k |
| Cost of Revenue | US$180.23k |
| Gross Profit | US$95.66k |
| Other Expenses | -US$415.36k |
| Earnings | US$511.02k |
Last Reported Earnings
Jul 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0033 |
| Gross Margin | 34.67% |
| Net Profit Margin | 185.23% |
| Debt/Equity Ratio | -47.5% |
How did 3K7A perform over the long term?
See historical performance and comparison